SoftBank is reportedly considering an investment of between $200m and $350m in CureFit, whose existing investors include the University of California-backed UC-RNT Fund.

Building on joint research from University of Vienna and Medical University of Vienna, P4 is creating next-generation platinum chemotherapy with fewer side-effects than current approaches.

GuideWell Mutual, Teladoc and Workday all contributed to a round that boosted the online physical and behavioural healthcare portal's total funding to $53m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The AbbVie Ventures-backed neurodegenerative disease treatment developer floated in the middle of its range having previously raised $129m in funding.

Dassault Systèmes has led a $56.5m series B round for health monitor developer BioSerenity, which also welcomed back return investors Idinvest Partners, LBO France and BPIfrance.

The cancer immunotherapy developer has added $37m to increase a series C round featuring Celgene and Alphabet unit GV to $97m.

A collaborative research fund established by Imperial and TUM has made its public debut with at least 12 projects in its portfolio focused on areas including healthcare, energy and industry.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Alexandria Venture Investments-backed genetic disease therapy developer is floating above its range having increased the number of shares in the offering.